Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
as soon as is submitted to ZB.
Type 1 diabetes and engineering enhanced islet transplantation.
Adv. Drug Deliv. Rev. 189:114481 (2022)
The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Biomaterials ; Cell And Tissue Engineering ; Cell Therapies ; Implantation Devices ; Islet Biology
ISSN (print) / ISBN
0169-409X
e-ISSN
1872-8294
Journal
Advanced Drug Delivery Reviews
Quellenangaben
Volume: 189,
Article Number: 114481
Publishing Place
Amsterdam
Non-patent literature
Publications
Reviewing status
Peer reviewed